RPCEC00000240招募中2 期
Clinical trial of combined immunotherapy con with allergenic extracts Dermatophagoides pteronyssinus (VALERGEN-DP) and Blomia tropicalis (VALERGEN-BT) by sublingual route in sensitized asthmatic adults (version 1.3).
ational Center of Bioproducts (BIOCEN)0 个研究点目标入组 120 人开始时间: 2017年2月17日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized controlled trial. Masking: Double Blind. Control group: Active. Assignment: Parallel. Purpose: Treatment
入排标准
- 年龄范围
- 18 years 至 45 years (—)
- 性别
- All
入选标准
- •1. Asthmatic allergic patients with positive responses during the preliminary survey in the following aspects: family and personal history of atopy, clinical symptoms only triggered when exposed to dust at home, mainly indoors, when getting up in the morning or going to bed at night.
- •2. Skin test positive with similar diameter (difference not mayor of 2 mm) to allergenic extracts of D. pteronyssinus and B. tropicalis, VALERGEN, 20,000 BU/ml.
- •3. Patients included in the study will be patients clinically diagnosed as extrinsic asthmatics who, according the clinical-therapeutic identification booklet, are classified as mild or moderate persistent patients in keeping with the International Consensus on Asthma Diagnosis and Treatment (GINA).
- •4. Age between 18 and 45 years.
- •5. Any gender and skin color.
- •6. Patients expressing their consent in writing to participate in clinical trial.
排除标准
- •1. Patients on allergenic extract immunotherapy during the two preceding years.
- •2. Patients classified as intermittent or severe persistent asthmatics after being interviewed.
- •3. Patients with a diagnosed autoimmune disease of any kind.
- •4. Generalized severe eczema.
- •5. Patients with diagnosed tumor disease.
- •6. Patients on beta-blocker treatment.
- •7. Patients with psychiatric disorders.
- •8. Patients not cooperating with treatment.
- •9. Patients who, at least one year before the study, needed immunestimulant or immunesuppressor treatment (no corticosteroids), including interferon and cyclosporine A.
- •10. Pregnancy and breastfeeding.
- •11. Adrenalin-contraindicated patients (high blood pressure).
- •12. Patients who, at least one year before the study, were under non-conventional treatments such as: Vimang, Aloe, ozone, banana capsules.
研究者
相似试验
已完成
1 期
A phase I study of combination immunotherapy with five peptides cocktail, CpG, and immune modulators for patients with advanced or metastatic colorectal cancercolorectal cancerJPRN-UMIN000022082Yamaguchi University12
进行中(未招募)
1 期
Phase III trial of combined immunochemotherapy with Fludarabine, Cyclophosphamide and Rituximab (FCR) versus Bendamustine and Rituximab (BR) in patients with previously untreated chronic lymphocytic leukaemia - CLL10EUCTR2007-007587-21-DKGCLLSG - Dept. of Internal Medicine I, University Hospital Cologne550
进行中(未招募)
1 期
Patients who suffer from chronic lymphocytic leukemia and have not received any chemotherapy so far will be treated with fludarabine, cyclophosphamide and rituximab (FCR) or bendamustine and rituximab (BR)EUCTR2007-007587-21-ATniversity of Cologne, Sponsor-Quality Management550
进行中(未招募)
1 期
Phase III trial of combined immunochemotherapy with Fludarabine, Cyclophosphamide and Rituximab (FCR) versus Bendamustine and Rituximab (BR) in patients with previously untreated chronic lymphocytic leukemiaEUCTR2007-007587-21-DEniversity of Cologne550
进行中(未招募)
1 期
Phase III trial of combined immunochemotherapy with Fludarabine, Cyclophosphamide and Rituximab (FCR) versus Bendamustine and Rituximab (BR) in patients with previously untreated chronic lymphocytic leukemia - CLL10patients (age 18 years or older) with chronic lymphocytic leukemia: Stage Binet C or stage Binet B and A requiring treatmentMedDRA version: 14.0Level: LLTClassification code 10009310Term: CLLSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2007-007587-21-CZGCLLSG - Dept. of Internal Medicine I, University Hospital Cologne550
